Pancreatic Cancer Clinical Trials 2026: Daraxonrasib, Elraglusib, and KRAS Breakthroughs
213 pancreatic cancer trials indexed, 108 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Pancreatic Cancer
Pancreatic cancer is a disease where malignant cells form in the tissues of the pancreas, an organ behind the stomach. The most common type is pancreatic ductal adenocarcinoma, which starts in the ducts that carry digestive enzymes. This cancer often develops silently, making early diagnosis difficult. Doctors use imaging tests such as CT scans and MRIs, along with biopsies, to confirm the diagnosis. Blood tests may also check for tumor markers, but these are not definitive on their own.
Symptoms of pancreatic cancer can include abdominal pain, weight loss, jaundice (yellowing of the skin and eyes), and digestive problems. These signs often appear only when the disease is advanced. Pancreatic cancer typically affects adults over 60 years old, though it can occur earlier. Risk factors include a family history of the disease, smoking, chronic pancreatitis, diabetes, and certain genetic mutations. The KRAS gene mutation is found in about 90% of pancreatic cancers, making it a key focus for research.
This cancer is medically and socially important because it has one of the highest mortality rates among cancers. In the United States, pancreatic cancer accounts for about 3% of all new cancer cases but nearly 7% of cancer deaths. The five-year survival rate remains below 12%, reflecting the difficulty in detecting and treating it early. The economic burden is also significant, with high costs related to treatment and lost productivity. These factors highlight the urgent need for better therapies and early detection methods.
The Pancreatic Cancer Treatment Landscape
For newly diagnosed pancreatic cancer, especially when surgery is not an option, the first-line treatment usually involves chemotherapy. Common regimens include FOLFIRINOX, a combination of four drugs, or gemcitabine with nab-paclitaxel. These treatments aim to slow tumor growth and improve symptoms. Surgery may be considered if the cancer is localized and operable, often followed by chemotherapy to reduce the risk of recurrence. Radiation therapy can also be part of the initial treatment plan in some cases.
When the disease progresses or does not respond to first-line therapy, second- and third-line treatments are considered. These options may include other chemotherapy drugs or targeted therapies. For example, some patients with specific genetic mutations might receive PARP inhibitors. Immunotherapy has shown limited success so far in pancreatic cancer but is being studied extensively. Drugs targeting the KRAS mutation, such as adagrasib and sotorasib, are under investigation and represent a new class of targeted treatments aiming to block the cancer-driving mutation directly.
Despite these options, many patients face challenges such as drug resistance, severe side effects, and limited effectiveness. Some subgroups, especially those with metastatic disease, respond poorly to current treatments. This creates a critical need for new therapies that can improve survival and quality of life. Research is focusing on targeting the KRAS mutation more effectively, as seen with daraxonrasib, a pan-KRAS inhibitor reported in 2026 to improve overall survival by about 60% in metastatic pancreatic cancer patients who had previous treatments. Another drug, elraglusib, showed promising results by roughly doubling one-year survival in a Phase 2 trial. These developments are part of a broader effort to fill gaps in treatment.
Why Clinical Trials Matter for Pancreatic Cancer
Clinical trials offer patients access to new treatments that are not yet widely available. This can be important for those with advanced pancreatic cancer who have exhausted standard options. Trials also provide closer monitoring by medical teams and contribute valuable information to science that may help future patients. Currently, there are 213 pancreatic cancer clinical trials indexed on ClinicalTrials.gov, with 108 actively recruiting participants. This range of studies includes tests of new drugs, combinations, and approaches targeting KRAS mutations and other pathways.
Participating in a clinical trial carries risks. The effectiveness of the treatment is not guaranteed, and some patients may receive a placebo or standard therapy instead of the experimental drug. Additional clinic visits, tests, and procedures may be required, which can be time-consuming and stressful. Side effects from new treatments may also be unknown or more severe than expected. Patients and caregivers should weigh these factors carefully and discuss them with their healthcare team before enrolling.
Clinical trials for pancreatic cancer are sponsored by a mix of academic institutions, pharmaceutical companies, and cooperative groups. These organizations work together to design and conduct studies that meet regulatory standards. ClinicalTrials.gov serves as a central registry, providing up-to-date information on trial availability, eligibility criteria, and locations. This transparency helps patients and doctors find suitable studies and supports the progress of research in this challenging disease area.
What to Look for in a Pancreatic Cancer Clinical Trial
Clinical trials are organized into phases that show how new treatments are tested and evaluated. Phase 1 trials focus on safety and dosage, usually involving a small number of participants. Phase 2 trials look at effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment against the current standard to confirm its benefits and monitor adverse reactions. Phase 4 happens after approval, tracking long-term effects. For pancreatic cancer, most trials are early-stage: 71 are Phase 1, 49 are Phase 2, 8 are Phase 3, and 40 have no phase listed. This means many studies are still exploring safety and initial effectiveness of new therapies.
When considering a pancreatic cancer trial, you will see specific inclusion criteria. These often include age limits, such as 18 years or older, to ensure safety. Prior treatments may be required or restricted, depending on the trial goals. Some trials need certain biomarkers, like KRAS mutations, to target treatments like daraxonrasib or adagrasib. Disease stage is also important; metastatic or locally advanced pancreatic cancer patients might be eligible. The duration of disease and overall health status can affect eligibility, as trials aim to enroll patients who can safely complete the study.
Exclusion criteria help protect participants from risks. Patients with other serious health problems, such as heart or liver disease, might be excluded. Drug interactions are also a concern, especially if patients take medications that could interfere with the trial drug. Safety thresholds like blood counts or organ function levels must be met to reduce the chance of harm. These criteria ensure that the trial results are reliable and that participants are not exposed to avoidable dangers.
Joining a clinical trial involves practical considerations. Trial length can range from a few months to several years, depending on the study design. Visit schedules may require frequent trips to the study site for tests and treatment. Travel distance and costs can be a challenge for some patients. Before enrolling, it is helpful to ask the research team these questions: What are the potential benefits and risks? How often will I need to visit the clinic? Are there costs not covered by insurance? What happens if I experience side effects or want to leave the trial early? These questions help patients and caregivers make informed decisions.
Primary Sources and Further Reading
For more information on pancreatic cancer and clinical trials, it is important to refer to trusted sources. These websites provide up-to-date details on treatment options, research studies, and patient support. They also offer guidance on how to find and enroll in clinical trials. Here are some helpful links to explore:
- National Cancer Institute: Pancreatic Cancer
- ClinicalTrials.gov: Pancreatic Cancer Trials
- MedlinePlus: Pancreatic Cancer
- Centers for Disease Control and Prevention: Pancreatic Cancer
Latest Research and Emerging Treatments for Pancreatic Cancer (2026)
Recent pancreatic cancer research has focused on targeting the KRAS mutation, which is common in many pancreatic tumors. Daraxonrasib, a pan-KRAS inhibitor, showed about a 60% improvement in overall survival in a Phase 3 trial for patients with metastatic pancreatic ductal adenocarcinoma who had prior treatments (NCT07491445). This drug works by blocking multiple forms of the KRAS protein, which helps cancer cells grow. Another drug, elraglusib, reported Phase 2 results indicating it may double one-year survival rates in metastatic pancreatic cancer. These findings highlight new drugs for pancreatic cancer that could offer additional options beyond standard chemotherapy.
Several ongoing clinical trials are testing daraxonrasib in different settings. One Phase 3 study is evaluating daraxonrasib combined with chemotherapy as a first-line treatment for metastatic pancreatic cancer (NCT07491445). Another trial is exploring daraxonrasib after surgery to delay recurrence in pancreatic ductal adenocarcinoma (NCT07252232). These trials are important because they may help patients live longer or improve quality of life by targeting the cancer more precisely. Other drugs like adagrasib and sotorasib, which target specific KRAS mutations such as G12C, are also being studied, although KRAS G12D inhibitors like daraxonrasib are more relevant for pancreatic cancer due to mutation patterns.
Beyond KRAS inhibitors, research continues on improving radiation therapy and chemotherapy combinations. For example, a Phase 3 trial is testing higher dose radiation therapy for locally advanced pancreatic cancer to see if it extends survival compared to usual care (NCT06958328). Another study is evaluating chemotherapy with or without panitumumab for patients without KRAS mutations (NCT06998940). These efforts reflect the broader pancreatic cancer treatment landscape, where new drugs and approaches are being tested to address different patient needs. For patients and caregivers searching for pancreatic cancer new treatment 2026, these trials represent hope for more personalized and effective options in the near future.
Frequently asked questions about Pancreatic Cancer trials
How do I find Pancreatic Cancer clinical trials?
The authoritative source for Pancreatic Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 213 pancreatic cancer studies are currently indexed. You can search by entering "pancreatic cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new pancreatic cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Pancreatic Cancer trials in?
Across the 213 pancreatic cancer trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Pancreatic Cancer clinical trials are currently recruiting?
As of the latest scan, 108 pancreatic cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 213 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting pancreatic cancer trial matches their tracked condition.
Stay informed about pancreatic cancer research
Get a weekly briefing with the trials that matter most.